<Emphasis Type="Bold">Background: There have been several explorations of factors influencing the reimbursement decisions of the National Institute for Health and Clinical Excellence (NICE) but not of other UK-based health technology assessment (HTA) organizations. <Emphasis Type="Bold">Objective: This study aimed to explore the factors...</emphasis></emphasis>

Cost estimates for the drug of interest, its comparator and concomitant drugs are an important component of pharmacoeconomic evaluations. However, whilst in general considerable efforts are made by analysts to ensure valid and accurate parameter inputs, the methods for estimating drug costs are...

Accurate resource-use measurement is challenging within an economic evaluation, but is a fundamental requirement for estimating efficiency. Considerable research effort has been concentrated on the appropriate measurement of outcomes and the policy implications of economic evaluation, while...

Rationale: Economic evaluations of pharmaceuticals require that health outcomes include adverse as well as beneficial effects of therapy. When the incidence and/or severity of adverse drug reactions (ADRs) result in an unfavourable risk/benefit profile, regulatory authorities such as the EMEA...

Non-compliance with prescribed regimens poses a significant problem in clinical therapeutics - patients who do not take their medications according to the labelling instructions are at higher risk of treatment failure, and this may have adverse effects on health outcome and healthcare costs....